Adding Darolutamide to Hormone Therapy and Radiation Cut Metastasis or Death Risk 58% in Very High-Risk Prostate Cancer
Interim results from the phase 3 DASL-HiCaP trial suggest darolutamide lowered the risk of metastasis or death in men with very high-risk localized prostate cancer, but survival benefits remain unproven.
Medical Daily ·